These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
227 related articles for article (PubMed ID: 17599696)
1. Resistance to Alzheimer's pathology is associated with nuclear hypertrophy in neurons. Riudavets MA; Iacono D; Resnick SM; O'Brien R; Zonderman AB; Martin LJ; Rudow G; Pletnikova O; Troncoso JC Neurobiol Aging; 2007 Oct; 28(10):1484-92. PubMed ID: 17599696 [TBL] [Abstract][Full Text] [Related]
2. The Nun study: clinically silent AD, neuronal hypertrophy, and linguistic skills in early life. Iacono D; Markesbery WR; Gross M; Pletnikova O; Rudow G; Zandi P; Troncoso JC Neurology; 2009 Sep; 73(9):665-73. PubMed ID: 19587326 [TBL] [Abstract][Full Text] [Related]
4. Mild cognitive impairment and asymptomatic Alzheimer disease subjects: equivalent β-amyloid and tau loads with divergent cognitive outcomes. Iacono D; Resnick SM; O'Brien R; Zonderman AB; An Y; Pletnikova O; Rudow G; Crain B; Troncoso JC J Neuropathol Exp Neurol; 2014 Apr; 73(4):295-304. PubMed ID: 24607960 [TBL] [Abstract][Full Text] [Related]
5. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia. Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593 [TBL] [Abstract][Full Text] [Related]
6. Alteration of mTOR signaling occurs early in the progression of Alzheimer disease (AD): analysis of brain from subjects with pre-clinical AD, amnestic mild cognitive impairment and late-stage AD. Tramutola A; Triplett JC; Di Domenico F; Niedowicz DM; Murphy MP; Coccia R; Perluigi M; Butterfield DA J Neurochem; 2015 Jun; 133(5):739-49. PubMed ID: 25645581 [TBL] [Abstract][Full Text] [Related]
8. Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e. Susanto TA; Pua EP; Zhou J; J Alzheimers Dis; 2015; 45(1):253-68. PubMed ID: 25524955 [TBL] [Abstract][Full Text] [Related]
9. MRI and CSF studies in the early diagnosis of Alzheimer's disease. de Leon MJ; DeSanti S; Zinkowski R; Mehta PD; Pratico D; Segal S; Clark C; Kerkman D; DeBernardis J; Li J; Lair L; Reisberg B; Tsui W; Rusinek H J Intern Med; 2004 Sep; 256(3):205-23. PubMed ID: 15324364 [TBL] [Abstract][Full Text] [Related]
10. Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease. van Rossum IA; Visser PJ; Knol DL; van der Flier WM; Teunissen CE; Barkhof F; Blankenstein MA; Scheltens P J Alzheimers Dis; 2012; 29(2):319-27. PubMed ID: 22233766 [TBL] [Abstract][Full Text] [Related]
11. In vivo detection of microstructural correlates of brain pathology in preclinical and early Alzheimer Disease with magnetic resonance imaging. Zhao Y; Raichle ME; Wen J; Benzinger TL; Fagan AM; Hassenstab J; Vlassenko AG; Luo J; Cairns NJ; Christensen JJ; Morris JC; Yablonskiy DA Neuroimage; 2017 Mar; 148():296-304. PubMed ID: 27989773 [TBL] [Abstract][Full Text] [Related]
12. Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps. Apostolova LG; Dutton RA; Dinov ID; Hayashi KM; Toga AW; Cummings JL; Thompson PM Arch Neurol; 2006 May; 63(5):693-9. PubMed ID: 16682538 [TBL] [Abstract][Full Text] [Related]
13. CSF biomarkers, impairment of cerebral hemodynamics and degree of cognitive decline in Alzheimer's and mixed dementia. Stefani A; Sancesario G; Pierantozzi M; Leone G; Galati S; Hainsworth AH; Diomedi M J Neurol Sci; 2009 Aug; 283(1-2):109-15. PubMed ID: 19278690 [TBL] [Abstract][Full Text] [Related]
14. Imaging beta-amyloid burden in aging and dementia. Rowe CC; Ng S; Ackermann U; Gong SJ; Pike K; Savage G; Cowie TF; Dickinson KL; Maruff P; Darby D; Smith C; Woodward M; Merory J; Tochon-Danguy H; O'Keefe G; Klunk WE; Mathis CA; Price JC; Masters CL; Villemagne VL Neurology; 2007 May; 68(20):1718-25. PubMed ID: 17502554 [TBL] [Abstract][Full Text] [Related]
15. Cerebrospinal fluid tau protein and periventricular white matter lesions in patients with mild cognitive impairment: implications for 2 major pathways. Maruyama M; Matsui T; Tanji H; Nemoto M; Tomita N; Ootsuki M; Arai H; Sasaki H Arch Neurol; 2004 May; 61(5):716-20. PubMed ID: 15148149 [TBL] [Abstract][Full Text] [Related]
16. Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment. Brys M; Pirraglia E; Rich K; Rolstad S; Mosconi L; Switalski R; Glodzik-Sobanska L; De Santi S; Zinkowski R; Mehta P; Pratico D; Saint Louis LA; Wallin A; Blennow K; de Leon MJ Neurobiol Aging; 2009 May; 30(5):682-90. PubMed ID: 17889968 [TBL] [Abstract][Full Text] [Related]
17. Loss of nucleus basalis neurons containing trkA immunoreactivity in individuals with mild cognitive impairment and early Alzheimer's disease. Mufson EJ; Ma SY; Cochran EJ; Bennett DA; Beckett LA; Jaffar S; Saragovi HU; Kordower JH J Comp Neurol; 2000 Nov; 427(1):19-30. PubMed ID: 11042589 [TBL] [Abstract][Full Text] [Related]